NCT05088499

Brief Summary

This is a GWAS study that aims to identify possible candidate genes associate to epilepsy by exploring single nucleotide polymorphism (SNP) in a group of epilepsy, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with epilepsy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2021

Completed
27 days until next milestone

First Posted

Study publicly available on registry

October 22, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

February 1, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

12 months

First QC Date

September 25, 2021

Last Update Submit

March 13, 2023

Conditions

Epilepsy

Keywords

GWAS

Outcome Measures

Primary Outcomes (1)

  • number of SNPs associated with epilepsy

    Using GWAS to identify candidate genes associate with epilepsy

    1 year

Study Arms (2)

Experimental group:

Patients with epilepsy

Genetic: DNA analysis

Control group

Patients without epilepsy

Genetic: DNA analysis

Interventions

DNA analysisGENETIC

GWAS

Control groupExperimental group:

Eligibility Criteria

Age0 Years - 5 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Children of Kazakh ethnic group

You may qualify if:

  • Children with seizures, confirmed by EEG and no morphological damage to the brain, confirmed by MRI of the brain;
  • The age of the patients is from 0 to 5 years;
  • Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;
  • Children are parents or legal guardians who have given written informed consent.

You may not qualify if:

  • Children over 5 years old;
  • Children whose parents, according to the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  • Children with seizures with brain damage that cause epilepsy;
  • Children of a non-Kazakh ethnic group.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Altynshash Jaxybayeva

Almaty, Kazakhstan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Epilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Altynshash Jaxybayeva

    Astana Medical University, Nur-Sultan, Kazakhstan

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Laboratory of Experimental Medicine

Study Record Dates

First Submitted

September 25, 2021

First Posted

October 22, 2021

Study Start

February 1, 2022

Primary Completion

January 20, 2023

Study Completion

January 20, 2023

Last Updated

March 14, 2023

Record last verified: 2023-03

Locations

KA(1)